Is there any benefit to giving pelvic radiation prior to systemic chemotherapy or vice versa for a patient with stage IIIA uterine serous carcinoma?

At our institution we take the data from PORTEC III and generally apply it to all patients with Stage III disease given the improvement in OS and DFS. This was one of the largest inclusions of serous patients at 16% in either group, although still a relatively small number. With this in mind, I also will check on Her-2 amplification and if present, will extrapolate the Fader et al. data to the 4 cycles of adjuvant carboplatin/paclitaxel and add Herceptin.